Cross-Priming by CD40xTAA Bispecific Antibodies “Results in Superior Antitumor Response”

01.30.23

Cross-Priming by CD40xTAA Bispecific Antibodies “Results in Superior Antitumor Response”

by Eleanor Mayfield, ELS

Cross-Priming by CD40xTAA Bispecific Antibodies “Results in Superior Antitumor Response”

01.13.23

Cross-Priming by CD40xTAA Bispecific Antibodies “Results in Superior Antitumor Response”

by Eleanor Mayfield, ELS

Small Study Finds Blinatumomab/Dasatinib Combination “Safe and Feasible” in Patients Aged Over 65 with Ph+ ALL

01.10.23

Small Study Finds Blinatumomab/Dasatinib Combination “Safe and Feasible” in Patients Aged Over 65 with Ph+ ALL

by Eleanor Mayfield, ELS

Novel Therapeutic Strategies “Highlight Need to Understand Underlying Molecular Processes” in Hematologic Cancers

12.12.22

Novel Therapeutic Strategies “Highlight Need to Understand Underlying Molecular Processes” in Hematologic Cancers

by Eleanor Mayfield, ELS

BiTEs Complement CAR T Cell Use in Solid Tumors

08.30.22

BiTEs Complement CAR T Cell Use in Solid Tumors

by ASTCT Science Highlights

BiTE-Secreting T Cells “More Effective” At Eradicating Leukemia Than 2G CAR T CD19 Cells

05.25.22

BiTE-Secreting T Cells “More Effective” At Eradicating Leukemia Than 2G CAR T CD19 Cells

by ASTCT

BCMA/CD16a Tetravalent Antibody Shows “Modest Activity” Against RRMM in First-in-Humans Trial

03.10.22

BCMA/CD16a Tetravalent Antibody Shows “Modest Activity” Against RRMM in First-in-Humans Trial

by ASTCT

Ex Vivo Study Identifies Determinants of Response to Bispecific Antibodies

03.08.22

Ex Vivo Study Identifies Determinants of Response to Bispecific Antibodies

by ASTCT

CAR T Therapy, BiTES Key to “Spectacular” Progress Against R/R DLBCL

11.19.21

CAR T Therapy, BiTES Key to “Spectacular” Progress Against R/R DLBCL

by ASTCT

Theme picker